JPWO2020232274A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020232274A5 JPWO2020232274A5 JP2021568611A JP2021568611A JPWO2020232274A5 JP WO2020232274 A5 JPWO2020232274 A5 JP WO2020232274A5 JP 2021568611 A JP2021568611 A JP 2021568611A JP 2021568611 A JP2021568611 A JP 2021568611A JP WO2020232274 A5 JPWO2020232274 A5 JP WO2020232274A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- compound
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 12
- 230000000155 isotopic effect Effects 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 229920000858 Cyclodextrin Polymers 0.000 claims 7
- 239000008139 complexing agent Substances 0.000 claims 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 7
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000003995 emulsifying agent Substances 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- 238000010254 subcutaneous injection Methods 0.000 claims 3
- 239000007929 subcutaneous injection Substances 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 229960001950 benzethonium chloride Drugs 0.000 claims 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical group [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025062046A JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848420P | 2019-05-15 | 2019-05-15 | |
| US62/848,420 | 2019-05-15 | ||
| PCT/US2020/032941 WO2020232274A1 (en) | 2019-05-15 | 2020-05-14 | Ketamine formulation for subcutaneous injection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062046A Division JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533971A JP2022533971A (ja) | 2022-07-27 |
| JP2022533971A5 JP2022533971A5 (https=) | 2023-05-23 |
| JPWO2020232274A5 true JPWO2020232274A5 (https=) | 2023-05-23 |
Family
ID=73230954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568611A Pending JP2022533971A (ja) | 2019-05-15 | 2020-05-14 | 皮下注射のためのケタミン製剤 |
| JP2025062046A Pending JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062046A Pending JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10973780B2 (https=) |
| EP (1) | EP3968979A4 (https=) |
| JP (2) | JP2022533971A (https=) |
| CN (2) | CN121489917A (https=) |
| CA (1) | CA3140046A1 (https=) |
| WO (1) | WO2020232274A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| CN121489917A (zh) * | 2019-05-15 | 2026-02-10 | 贝克森生物医药公司 | 用于皮下注射的氯胺酮制剂 |
| JP7814375B2 (ja) | 2020-08-18 | 2026-02-16 | オークウッド ラボラトリーズ，エル．エル．シー． | ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法 |
| WO2022109050A1 (en) * | 2020-11-18 | 2022-05-27 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds |
| JP2023551145A (ja) | 2020-11-18 | 2023-12-07 | ベクソン バイオメディカル，インク． | 医薬化合物の錯化剤塩製剤 |
| CA3245931A1 (en) * | 2022-03-14 | 2023-09-21 | Perception Neuroscience, Inc. | R-KETAMINE PHARMACEUTICAL FORMULATIONS |
| US20250345458A1 (en) * | 2022-05-18 | 2025-11-13 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios |
| IN202221054235A (https=) | 2022-09-22 | 2023-11-03 | ||
| CN120936348A (zh) * | 2023-02-15 | 2025-11-11 | 克力迈实验室公司 | 任选地与n-酰基乙醇胺组合地包含氯胺酮的组合物及其用途 |
| US12005035B1 (en) * | 2023-08-14 | 2024-06-11 | Daniel C. Javitt | Compositions and methods for treatment of chronic pain and depression |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| WO1997007750A1 (en) * | 1995-08-30 | 1997-03-06 | Weg Stuart L | Administration of ketamine to manage pain and to reduce drug dependency |
| ATE367828T1 (de) * | 1998-04-03 | 2007-08-15 | Novartis Vaccines & Diagnostic | Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel |
| CN1172908C (zh) | 1999-12-10 | 2004-10-27 | 中国科学院上海药物研究所 | N-取代苄基或苯基芳香磺酰胺化合物及其用途 |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| AU2004308935A1 (en) * | 2003-12-22 | 2005-07-14 | Schering Corporation | Pharmaceutical compositions |
| CN1939298A (zh) | 2005-09-29 | 2007-04-04 | 中国科学院上海药物研究所 | 硫酸舒欣啶固体和靶向制剂及其制备方法 |
| WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| CN101765582A (zh) * | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| EP3904332B1 (en) * | 2011-10-14 | 2024-12-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
| EP2830604A4 (en) * | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
| US20130296437A1 (en) | 2012-05-04 | 2013-11-07 | E-Therapeutics Plc | Treatment of Depression |
| US10124940B2 (en) | 2012-09-11 | 2018-11-13 | Zolo Solutions, Inc. | Systems, methods, and devices for dispensing one or more substances |
| WO2017180589A1 (en) | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| CN121489917A (zh) * | 2019-05-15 | 2026-02-10 | 贝克森生物医药公司 | 用于皮下注射的氯胺酮制剂 |
-
2020
- 2020-05-14 CN CN202511966779.7A patent/CN121489917A/zh active Pending
- 2020-05-14 JP JP2021568611A patent/JP2022533971A/ja active Pending
- 2020-05-14 CA CA3140046A patent/CA3140046A1/en active Pending
- 2020-05-14 US US16/874,485 patent/US10973780B2/en active Active
- 2020-05-14 CN CN202080051484.6A patent/CN114126596A/zh active Pending
- 2020-05-14 WO PCT/US2020/032941 patent/WO2020232274A1/en not_active Ceased
- 2020-05-14 EP EP20804815.7A patent/EP3968979A4/en active Pending
-
2021
- 2021-02-26 US US17/187,641 patent/US20210186896A1/en active Pending
-
2025
- 2025-04-03 JP JP2025062046A patent/JP2025114555A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025114555A5 (https=) | ||
| JPWO2020232274A5 (https=) | ||
| KR810000900B1 (ko) | 항생물질 조성제의 안정화 방법 | |
| CN105899209B (zh) | 含有吡啶基氨基乙酸化合物的药物制剂 | |
| CN1684689A (zh) | 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂 | |
| JPWO2022000091A5 (https=) | ||
| CN110251516B (zh) | 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物 | |
| CN105828818B (zh) | 含有吡啶基氨基乙酸化合物的药物组合物 | |
| US20040209843A1 (en) | Aqueous cilostazol preparation for injection | |
| US20120202863A1 (en) | Compositions and methods for treatment of glaucoma | |
| CN113747881B (zh) | 呋塞米的浓缩液体药物制剂及其给药方法 | |
| JP3933683B2 (ja) | アジスロマイシン含有水性医薬組成物及びその調製方法 | |
| JP7062846B1 (ja) | 安定な医薬組成物 | |
| JP4011114B2 (ja) | 脳浮腫抑制剤 | |
| JP2009542589A (ja) | ４−［（（４−カルボキシブチル）−｛２−［（４−フェネチルベンジル）オキシ］−フェネチル｝アミノ）メチル］安息香酸の水性医薬製剤 | |
| WO2012108489A1 (ja) | 親水性薬物の薬物移行性を改善した水性組成物 | |
| US20040087513A1 (en) | New drug combinations based on sodium channel blockers and magnesium salts | |
| CN1812794B (zh) | 溶液药用组合物 | |
| JP7090845B2 (ja) | パロノセトロン含有液体組成物 | |
| CN103561766A (zh) | 作为辅助眼部降压药的s1p拮抗剂 | |
| JPWO2023144782A5 (https=) | ||
| JPWO2021189051A5 (https=) | ||
| US20040019075A1 (en) | New formulation for the parenteral application of crobenetine | |
| RU2024135677A (ru) | Комбинированная терапия недоношенных младенцев | |
| HK40074840B (zh) | 稳定的医药组合物 |